GeoVax Labs Inc.

GeoVax CEO Comments on Recent Changes in Capital Structure

GeoVax CEO Comments on Recent Changes in Capital Structure

Atlanta, GA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Dear GeoVax Stockholders,

In recent weeks, we have seen a significant rise in the number of our common shares outstanding, which stands at 95,627,584 as of September 30, 2019.  This increase is not due to new financings by GeoVax, but rather to the rapid liquidation of convertible preferred stock held by third party investors.  Concurrent with this letter, we have filed a Form 8-K with the SEC giving further details.  I encourage all shareholders to review this Form 8-K filing.

As of September 30, there remain 3,054 shares of unconverted preferred stock ($3,053,782 stated value), which the investors may continue to convert into common stock over the coming weeks.  As additional conversions occur, we will provide further updates via SEC filings in order to avoid selective disclosure to individual stockholders.

While this activity by the holders of our preferred stock is within their legal right, it has unfortunately produced severe downward pressure on the price of our common stock and the resultant market valuation of our company. This cannot be avoided.  No one is happy about this situation, and I understand the frustration and extreme disappointment this has caused among our stockholders, including ourselves.  But we look forward to the day in which the preferred stock is fully converted, thus simplifying our capital structure and allowing us to seek additional financing with better, more supportive terms.  In the interim, we continue to evaluate alternative options to support and improve the value of our stock and Company value.

With all of this said, the dilution of our common stock and decline of our stock price does not detract from the underlying potential of our company.  I encourage you to read my letter dated August 2, 2019 as well as our last quarterly update dated August 14, 2019, both of which are posted to our website ().  We continue to seek ways in which to overcome our financing challenges and move our product development efforts forward.  We will provide further updates as warranted.

Sincerely,

David Dodd

President & CEO

GeoVax Labs Inc.
678-384-7220
 
EN
01/10/2019

Reports on GeoVax Labs Inc.

 PRESS RELEASE

GeoVax Receives Notice of Allowance For Cancer Vaccine Patent

GeoVax Receives Notice of Allowance For Cancer Vaccine Patent Adds to Growing Portfolio of Intellectual Property Assets ATLANTA, Ga., Dec. 09, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No. 17/876,682 to GeoVax, titled “Vaccinia Viral Vectors Encoding Chimeric Virus Like Particles.” The allowed claims add to GeoVax’s intellectual property protection related...

 PRESS RELEASE

GeoVax to Present at the Noble Capital Markets Twentieth Annual Emergi...

GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference ATLANTA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will present at NobleCon20 - the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference taking place December 2-5, 2024 in Boca Raton, FL. Presentation Details:Speaker: David Dodd, Chairman & CEO Date/Time: December 3, 2024, 11:30 am ET Location: Flor...

 PRESS RELEASE

GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Tri...

GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia GEO-CM04S1 Improved Immune Response vs mRNA Vaccine ATLANTA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the completion of an interim data review by the Data Safety Monitoring Board (DSMB) for the ongoing Phase 2 clinical trial of GEO-CM04S1, GeoVax’s dual-antigen next-generation COVID-19 vaccine, a...

 PRESS RELEASE

GeoVax Reports Third Quarter 2024 Financial Results and Provides Busin...

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance into Phase 2 clinical trial for first recurrent head and neck cancer in the first half of 2025 GEO-MVA Mpox vaccine advancing with cGMP clinical batch anticipated during fourth quarter 2024 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, ...

 PRESS RELEASE

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corp...

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024 GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to pro...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch